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Background:N-methyl-D-aspartate receptor (NMDAR) antibodies havebeendocumented in the serumof individ-
uals with primary psychiatric disorders from several independent cohorts, but these ﬁndings have not been sys-
tematically assessed in aggregate or in relation to methodological covariates.
Methods: We searched MEDLINE, EMBASE, and PsycINFO for studies in any language that provided data on
NMDAR antibody seropositivity or absolute serum titers in schizophrenia or schizoaffective, bipolar, or major
depressive disorders. We used a random effects model to pool estimates across studies.
Results: Nine studies met the eligibility criteria. Five studies (3387 participants) provided data on NMDAR anti-
body seropositivity in psychiatric versus control groups based on high-speciﬁcity seropositivity thresholds
(cell-based assays [CBAs]: 1:320 dilution, 1:200 dilution, visual score N 1; enzyme-linked immunosorbent
assay [ELISA]: 90th percentile of control titers). Meta-analysis showed signiﬁcantly higher odds of NMDAR anti-
body seropositivity among those with schizophrenia or schizoaffective, bipolar, or major depressive disorders
compared with healthy controls (odds ratio [OR], 3.10; 95% conﬁdence interval [CI], 1.04–9.27; P= .043; I2 =
68%). Four studies (3194 participants) provided outcome data for these groups based on low-speciﬁcity seropos-
itivity thresholds (CBAs 1:10 dilution; ELISA: 75th percentile of control titers). Meta-analysis showed greater het-
erogeneity and no signiﬁcant between-group difference (OR, 2.31; 95% CI, 0.55–9.73; P = .25; I2 = 90%).
Seropositive participants in psychiatric groups had various combinations of IgG, IgM, and IgA class antibodies
against NR1, NR1/NR2B, and NR2A/NR2B subunits. Subgroup analysis revealed signiﬁcantly higher odds of sero-
positivity among all participants based on 1:10 versus 1:320 dilution seropositivity thresholds (OR, 4.56; 95% CI,
2.41–8.62; P b .001; I2 = 0%; studies = 2, n = 2920), but no apparent difference between ﬁrst-episode and
chronic schizophrenia or schizoaffective disorder (OR, 1.15; 95% CI, 0.19–7.24; P= .88, I2 = 43%, studies = 2,
n= 1108). Average NR2A/NR2B antibody titers determined by ELISA were signiﬁcantly higher among partici-
pants with ﬁrst-episode schizophrenia (P b .0001) and acute mania (P b .01) compared with healthy controls.
Levels decreased by 58% at 8 weeks in ﬁrst-episode schizophrenia, and by about 13% at 4 days in acute mania.
Conclusions: Individuals with schizophrenia or schizoaffective, bipolar, or major depressive disorders are collec-
tively about three times more likely to have elevated NMDAR antibody titers compared with healthy controls
based on high-speciﬁcity, but not low-speciﬁcity, seropositivity thresholds, though considerable methodological
and statistical heterogeneity exists. Evidence concerning the effect of disease state and time of serum acquisition
is varied and consistent, respectively. Adequately powered longitudinal studies employing standardized assay
methods and seropositivity threshold deﬁnitions, and quantifying NMDAR antibodies in both sera and cerebro-
spinal ﬂuid are needed to further elucidate the clinical and pathophysiological implications of this association.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).epartment of Neurology, NYU
0016-4852, USA. Tel.: +1 646
. This is an open access article under1. Introduction
N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated
ion channels that mediate higher cognitive function and synaptic
plasticity (recently reviewed by Paoletti et al., 2013). Each NMDAR
consists of two NR1 subunits, and two non-NR1 subunits (NR2A,
NR2B, NR2C, NR2D, NR3A, and/or NR3B). Each subunit, in turn,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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agonist-binding domain, a transmembrane domain, and an intracel-
lular C-terminal domain. Activation of NMDARs requires that co-
agonist glycine or D-serine binds the agonist-binding domain of the
NR1 subunits, and that glutamate binds the agonist-binding domain
of the two non-NR1 subunits.
Antibodies directed against NMDARs found in selected autoimmune
diseases are associated with acute and ﬁrst-episode neuropsychiatric
sequelae that resemble primary psychotic and mood disorders. The
pathophysiology of anti-NMDAR encephalitis — the prototype of these
disorders — is characterized by IgG class NMDAR antibodies binding
the N368/G369 region of the N-terminal domain of the NR1 subunit
on dendritic clusters (Gleichman et al., 2012), resulting in cross-
linking and internalization of these subunits in a dose-dependent man-
ner (Hughes et al., 2010). Up to two-thirds of patientswith anti-NMDAR
encephalitis, initially present to psychiatric, rather than neurological,
services (Dalmau et al., 2008). Kayser and colleagues found that
the prevalence of isolated psychiatric presentations of anti-NMDAR
encephalitis was 4% (23 of 571)—including ﬁve cases presenting at
ﬁrst-episode and eight cases presenting during acute relapses (Kayser
et al., 2013). NMDAR antibodies are also implicated in neuropsychiatric
systemic lupus erythematosus, whereby IgG class NMDAR antibodies
are thought to interact with the allosteric zinc-binding site on the
agonist-binding domain of NR2A and NR2B subunits (Omdal et al.,
2005; Lapteva et al., 2006; Arinuma et al., 2008; Gono et al., 2011).
Once bound, these antibodies can promote NMDAR-mediated
excitotoxicity via upregulation of neuronal mitochondrial perme-
ability (Faust et al., 2010) and intracellular Ca2+ inﬂux (Gono et al.,
2011). Further, they can increase blood–brain permeability by
upregulating endothelial inﬂammatory and vascular alterations
(Yoshio et al., 2013). Among those with neuropsychiatric systemic
lupus erythematosus, NMDAR antibodies have been speciﬁcally as-
sociated with depressive mood and psychosis as opposed to focal
neurological sequelae (Lauvsnes and Omdal, 2012). NMDAR anti-
bodies have also been associated with progressive cognitive impair-
ment (Pruss et al., 2012b), primary Sjögren's syndrome (Lauvsnes
et al., 2013) and herpes simplex encephalitis (Prüss et al., 2012;
Armangue et al., 2014).
AlthoughNMDARantibodies have been linked to psychiatric sequel-
ae secondary to autoimmune diseases, and both NMDAR dysfunction
(Olney and Farber, 1995; Jentsch and Roth, 1999) and comorbid auto-
immune disease (Eaton et al., 2010; Benros et al., 2013; Benros et al.,
2014a; Benros et al., 2014b) have been consistently linked to primary
psychiatric disorders, the relationship between NMDAR antibodies
and primary psychiatric disorders is less clear. Over the last 4 years, sev-
eral studies have yielded mixed ﬁndings concerning this relationship
(Ezeoke et al., 2013; Pollak et al., 2013). There are no systematic reviews
to date evaluating the relationship betweenNMDAR antibodies and bipo-
lar ormajor depressive disorders, or addressing the effects of covar-
iates such as NMDAR-subunit/immunoglobulin-class combinations
assessed versus identiﬁed, timing of serum acquisition, disease
state severity, medication status, or assay methods, including the
dilution cut-off points used to deﬁne seropositivity. Here, we
aimed to address these remaining gaps in the literature by
performing a systematic review with a meta-analysis of the associ-
ation between NMDAR antibodies and schizophrenia and
schizoaffective disorder, as well as bipolar and major depressive dis-
orders. We also aimed to isolate sources of heterogeneity underlying
the mixed ﬁndings in the extant literature. We discuss our ﬁndings
in light of the implications for clinical practice and future etiologic
research in psychoimmunology.
2. Methods and materials
We devised the methods of this systematic review in accordance
with the MOOSE guidelines (Stroup et al., 2000).2.1. Search strategy
We sought potentially eligible studies for inclusion through a series
of electronic database searches within Ovid MEDLINE (1947–2014),
EMBASE (1974–2014), and PsycINFO (1808–2014); see Table S1 in
the Appendix for a copy of our full-length search strategy. We looked
for peer-reviewed journal articles (published data) and meeting ab-
stracts (unpublished data) written in any language. Searches were reg-
ularly updated through 26April 2014.We supplemented these searches
by handsearching the reference lists of included studies and of other
content-relevant articles. We also asked experts in the ﬁeld if they
were aware of any additional studies (12th Psychoimmunology Expert
Meeting; 6–9 March 2014; Günzburg, Germany).
2.2. Study selection
We deﬁned eligible studies as those using case–control, prospective
cohort, or cross-sectional designs and providing categorical (seroposi-
tive/seronegative) and/or continuous data (antibody titers) on
NMDAR antibodies in individuals with schizophrenia, schizoaffective
disorder, bipolar disorder, and/ormajor depressive disorder.We includ-
ed studies that involved participants enrolled at ﬁrst-episode presenta-
tions who were later diagnosed with one of these psychiatric disorders
after establishing symptom persistence (as required by diagnostic
criteria). To preserve intragroup homogeneity, we excluded partici-
pants with psychotic disorder not otherwise speciﬁed, delusional disor-
der, borderline personality disorder, comorbid autoimmune disease,
and non-healthy controls, as well as those whose initial diagnosis was
one of the eligible psychiatric disorders when the diagnosis was subse-
quently revised to anti-NMDAR encephalitis after obtaining antibody
test results (Table S2). This ensured that studies addressed the focus
of our research question regarding individuals with psychiatric disor-
ders, as the prevalence of isolated psychiatric manifestations of anti-
NMDAR encephalitis has been assessed directly elsewhere (Kayser
et al., 2013). Study eligibility was determined by consensus.
2.3. Data collection
We extracted data from the full-texts of included studies on
predeﬁned variables using a standardized and piloted data collection
form. To characterize included studies, we extracted data for eligibility
criteria, citation information, country of publication, participant recruit-
ment strategy, andmethods used for immunostaining assays. Data with
regard to the latter included assay technique, NMDAR subunits
assessed, immunoglobulin class antibodies assessed, blinding of prima-
ry outcome assessment, and dilution cut-off points or other criteria used
to deﬁne NMDAR antibody seropositivity. To characterize included
study participants, we extracted data for psychiatric and control groups
on age, gender, positive psychotic symptoms, and disease state inclu-
sion criteria. For the initial data extraction, we preserved any distinc-
tions regarding psychiatric disorders and disease states. For example,
wherever possible, we extracted data on participants with schizophre-
nia alone, rather than on participants with either schizophrenia or
schizoaffective disorder. Likewise, we extracted data for participants
with ﬁrst-episode schizophrenia, rather than on those with either
ﬁrst-episode or chronic schizophrenia. Last, we preserved any distinc-
tions with regard to the study time point of serum acquisition and in
the criteria constituting the operational deﬁnitions used to deﬁne the
threshold of NMDAR antibody immunoreactivity/titers indicative of a
seropositive versus seronegative test result (henceforth “seropositivity
thresholds”).
We deﬁned our primary outcome, NMDAR antibody seropositivity,
according to included study investigators' operational deﬁnitions as
provided in the original reports. We summarized primary outcome
data for each participant group, disease state, time of serum acquisition,
and seropositivity threshold as the odds of NMDAR antibody
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divided by the number of seronegative participants (non-events). Our
secondary outcome was serum titers of NMDAR antibodies in nano-
grams per milliliter. We summarized secondary outcome data for each
study group, disease state, and time of serum acquisition, as mean ±
standard deviation antibody titers.
2.4. Statistical analysis
For studies that provided primary outcome data on psychiatric and
healthy control groups, we calculated point estimate odds ratios
(ORs), with corresponding 95% conﬁdence intervals (CIs) equal to the
odds of NMDAR antibody seropositivity among participants with psy-
chiatric disorders divided by those of the healthy control group. We re-
peated these calculations for each study according to psychiatric
disorder, disease state, time of serum acquisition, and seropositivity
threshold. We performed meta-analysis on individual study point esti-
mates of NMDAR antibody seropositivity for psychiatric versus healthy
control groups based on high- and low-speciﬁcity seropositivity thresh-
olds. We performed subgroup analyses comparing distinct disease
states and seropositivity thresholds. For studies providing secondary
outcome data on psychiatric and healthy control groups, we calculated
the weighted mean difference with 95% CIs. Likewise, we repeated
this analysis for each psychiatric disorder, disease state, and time of
serum acquisition. We also extracted data on analysis of variance tests
of trend for the interaction of antibody titers and time.
We used theDerSimonian and Laird random effectsmodel to under-
take meta-analysis (DerSimonian and Laird, 1986). We chose a random
effects model because it generally yields more conservative estimates
than do ﬁxed-effect models such as the Mantel–Haenszel method.
Moreover, it is a more appropriate statistical test to address this speciﬁc
research question given the extent of methodological variability across
studies. Secondary outcome data were not pooled for the meta-
analysis because of insufﬁcient data.We tested for heterogeneity across
point estimates pooled for the meta-analysis by computing the χ2 sta-
tistic (Cochrane's Q), and applied the standard of P values less than
0.10 as indicative of statistically signiﬁcant heterogeneity. We quanti-
ﬁed any observed heterogeneity by computing the I2 statistic. We con-
sidered values of I2 ≤25%, ≤50%, and ≤75%, as indicative of low,
moderate, and high degrees of heterogeneity, respectively (Higgins
et al., 2003). We attempted to obtain any missing data on primary and
secondary outcome measures by emailing corresponding authors.
With the exception of the above-mentioned heterogeneity estimates,
we considered P values less than 0.05 statistically signiﬁcant.We under-
took all statistical analyses using Stata version 12.1 (StataCorp, LP.
College Station, TX, USA).
3. Results
3.1. Search results
Results of the study search and selection processes are shown in
Fig. S1. A total of nine studies met all eligibility criteria (Dickerson
et al., 2013; Govorin and Vasil'eva, 2011; Hammer et al., 2013;
Haussleiter et al., 2012; Masdeu et al., 2012; Rhoads et al., 2011;
Steiner et al., 2013; Tsutsui et al., 2012; Zandi et al., 2011; Table 1).
Most excluded studies were discernibly ineligible; one exception
was a retrospective cohort brieﬂy mentioned within a case report ar-
ticle, wherein the authors found 3 IgM class NMDAR antibody (un-
speciﬁed subunit(s)) seropositive participants among 70 patients
with a clinical diagnosis of psychosis not otherwise speciﬁed (Choe
et al., 2013). Among our included studies, two reported data across
more than one report: Dickerson et al. (2012) and Dickerson et al.
(2013), as well as Zandi et al. (2011) and Lennox et al. (2009). We
obtained an English translation for Govorin and Vasil'eva (2011),
which was written in Russian. We also obtained data on NMDARantibody seropositivity by disease state severity subgroups for
Hammer et al. (2013) from a published article wherein the authors
acquired these data via a personal communication (Pollak et al.,
2013). All other data were obtained directly from the original pub-
lished sources. Seven studies used HEK293 cell-based assays, and
two studies used enzyme-linked immunosorbent assays (ELISAs);
studies tested for varied combinations of immunoglobulin classes
and NMDAR subunits (Table 1). Characteristics of included study
participants are summarized in Table 2.
3.2. Primary outcome: N-methyl-D-aspartate receptor antibody seropositivity
Eight studies provided primary outcome data for one or more psy-
chiatric groups (Fig. 1); the exception was Govorin and Vasil'eva
(2011). Six of these studies also provided primary outcome data for a
healthy control group (Rhoads et al., 2011; Zandi et al., 2011; Masdeu
et al., 2012; Dickerson et al., 2013; Hammer et al., 2013; Steiner et al.,
2013).
Five studies (3387 participants) provided data on NMDAR antibody
seropositivity based on high-speciﬁcity seropositivity thresholds.
Dickerson et al. (2013) used the 90th percentile of control titers,
Masdeu et al. (2012) used 1:200 dilution, and Zandi et al. (2011) used
a visual score of immunoreactivity greater than one (as described by
Irani et al., 2010). Steiner et al. (2013) andHammer et al. (2013) provid-
ed seropositivity data based on serial titrations. For these studies, we
chose 1:320 dilution as the high-speciﬁcity threshold because it was
the lowest common denominator between them that exceeded 1:10
dilution and the clinically validated standard of 1:200 dilution used in
the context of diagnosing anti-NMDAR encephalitis (Dalmau et al.,
2008). Meta-analysis showed signiﬁcantly higher odds of NMDAR anti-
body seropositivity among participants with schizophrenia,
schizoaffective disorder, bipolar disorder, or major depressive disorder,
as compared with healthy controls (OR, 3.10; 95% CI, 1.04–9.27, P =
.043; Fig. 2A). There was a moderate degree of statistically signiﬁcant
heterogeneity across the individual study point estimates contributing
to this summary estimate (I2 = 68%, P= .025).
Four studies (3194 participants) provided data on NMDAR antibody
seropositivity based on low-speciﬁcity thresholds. Dickerson et al.
(2013) used the 75th percentile of control titers, whereas the remaining
three studies used 1:10 dilution (Rhoads et al., 2011; Hammer et al.,
2013; Steiner et al., 2013). The summary estimate showed a statistically
insigniﬁcant increase in the odds of NMDAR antibody seropositivity
among participants with schizophrenia or schizoaffective, bipolar, or
major depressive disorders, as compared with healthy controls (OR,
2.31; 95% CI, 0.55–9.73; P = .25; Fig. 2B). There was a high degree of
statistically signiﬁcant heterogeneity across the individual study point
estimates contributing to this summary estimate (I2 = 90%, P b .001).
Two studies (1108 participants) provided data on NMDAR antibody
seropositivity for two or more distinct disease states (Zandi et al., 2011;
Hammer et al., 2013). Meta-analysis showed no statistically signiﬁcant
difference between the odds of NMDAR antibody seropositivity among
132 participantswithﬁrst-episode schizophrenia or schizoaffective disor-
der as compared with 976 participants with chronic schizophrenia or
schizoaffective disorder (OR, 1.15; 95% CI, 0.19–7.24; P = .88; Fig. 3A).
There was a moderate degree of heterogeneity across studies, which
was not statistically signiﬁcant (I2 = 43%, P= .19).
Two studies (2920 participants) provided data on NMDAR anti-
body seropositivity for two or more distinct seropositivity thresh-
olds (Hammer et al., 2013; Steiner et al., 2013). The summary
estimate showed that all participants, including those in psychiatric
or healthy control groups, were four and one-half times more likely
to test seropositive for NMDAR antibodies based on a 1:320 dilution
seropositivity threshold as compared with a 1:10 dilution seroposi-
tivity threshold (OR, 4.56; 95% CI, 2.41–8.62; P b .001; Fig. 3B).
There was a moderate degree of statistically insigniﬁcant heteroge-
neity across point estimates (I2 = 44%, P = .18). For the study by
Table 1
Included studies.
Consecutive Blinded CBA b ELISA c NR1 NR1/NR2B NR2A/NR2B IgG IgM IgA
Hammer et al. (2013)a ? ● ● ○ ● ● ○ ● ● ●
Steiner et al. (2013)a ● ● ● ○ ● ● ○ ● ● ●
Dickerson et al. (2013) ● ? ○ ● ● ○ ● ● ○ ○
Haussleiter et al. (2012) ? ? ● ○ ● ● ○ ? ? ?
Tsutsui et al. (2012) ? ? ● ○ ○ ● ○ ● ○ ○
Masdeu et al. (2012) ? ● ● ○ ● ○ ○ ● ○ ○
Zandi et al. (2011) ● ● ● ○ ○ ● ○ ● ○ ○
Rhoads et al. (2011) ? ? ● ○ ● ○ ○ ● ○ ○
Govorin and Vasil'eva (2011) ? ? ○ ● ○ ○ ● ? ? ?
Included study participant enrollment strategy (consecutive series vs. convenience sample), masking of outcome assessment (blinded vs. un-blinded to case/control status), type of assay
(cell-based assay vs. enzyme-linked immunosorbent assay), N-methyl-D-aspartate receptor antibody subunits assessed (NR1, NR1/NR2B, NRA/NR2B), and immunoglobulin classes
assessed (IgG, IgM, IgA).
● = yes; ? = unclear/not reported; ○ = no; CBA = cell-based assay; ELISA = enzyme-linked immunosorbent assay; Ig = immunoglobulin.
a Refers to studies that reported the maximum dilution at which immunoreactivity was observed for each participant's sample.
b Human embryonic kidney (HEK293) cell-based assays.
c Gold Dot Test, CIS Biotech, Inc., Atlanta, GA, USA.
Table 2
Study participants.a
N Age, years Male sex PANSS P1–P7
Hammer et al. (2013)
Schizophrenia (n = 881) or schizoaffective (n = 200) 1081 39 (13) 723 (67) 14 (6)
First episode 101 .. .. .. .. .. ..
Chronic 954 .. .. .. .. .. ..
Unspeciﬁed 26 .. .. .. .. .. ..
Bipolar disorder or major depressive disorder (NR) 148 50 (16) 70 (47) .. ..
Healthy controls 1272 37 (13) 780 (61) .. ..
Steiner et al. (2013)
Schizophrenia 119 36 (11) 77 (65) 22 (6)
First episode 45 .. .. .. .. .. ..
Acute (unmedicated for ≥6 weeks) 74 .. .. .. .. .. ..
Major depressive disorder (acute/ﬁrst episode) 70 40 (12) 26 (37) 9 (2)
First episode 35 .. .. .. .. .. ..
Acute (unmedicated for ≥6 weeks) 35 .. .. .. .. .. ..
Healthy controls 230 36 (12) 159 (69) .. ..
Dickerson et al. (2013)
Acute maniab 57 35 (13) 16 (28) .. ..
Schizophrenia or schizoaffective disorder (multi-episode, chronic) 234 42 (12) 137 (59) .. ..
Bipolar disorder (acute depressive state) 28 38 (14) 6 (21) .. ..
Healthy controls 207 33 (11) 80 (39) .. ..
Haussleiter et al. (2012)
Schizophrenia (NR) 44 43 (13) 15 (34) 21 (7)
Schizoaffective disorder (NR) 4 45 (7) 1 (25) 13 (3)
Tsutsui et al. (2012)
Schizophrenia, Schizoaffective disorder, or brief psychosis (NR) 51 .. (15–72)c 10 (20) .. ..
Schizoaffective disorderd 3 32 (6) 1 (33) .. ..
Masdeu et al. (2012)
Schizophrenia (ﬁrst episode) 80 29 (10) 58 (73) .. ..
Healthy controls 40 31 (9) 25 (62) .. ..
Zandi et al. (2011)
Schizophrenia 53 .. .. .. .. .. ..
First episode 31 .. .. .. .. .. ..
Chronice 22 .. .. .. .. .. ..
Bipolar or Major depressive disorders (ﬁrst episode)f 7 .. .. .. .. .. ..
Healthy controlse 23 .. .. .. .. .. ..
Rhoads et al. (2011)
Schizophrenia (NR) 7 39 (10) 3 (43) .. ..
Healthy controls 3 23 (1) 1 (33) .. ..
Govorin and Vasil'eva (2011)
Schizophrenia (ﬁrst episode) 23 24 (6) 12 (52) 14 (2)
Healthy controls 10 24 (3) 4 (40) .. ..
NR = not reported; PANSS = Positive and Negative Syndrome Scale; P1–P7 = positive subscale.
a Values are mean (standard deviation) for continuous data, and number (percent) for categorical data.
b Bipolar 1 disorder manic episode, bipolar 2 disorder hypomanic episode, or schizoaffective disorder (bipolar type) manic, hypomanic, or mixed episode.
c Range.
d Comorbid narcolepsy.
e Primary outcome data was extracted from a meeting abstract reporting results from the same study.
f The participants with major depressive disorder were also observed as having psychotic features.
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0.01 0.10 1.00 10.00 100.00
Seropositivity
Threshold
Disease State Psychiatric group Healthy controls Odds Ratio (95% CI)
First Ep. Acute Multi Ep. Chronic Events Total % Events Total %
Hammer et al. (2013)
Schizophrenia or Schizoaffective disorder 1:10 dilution  6 101 5.9 137 1272 10.8 0.52
Schizophrenia or Schizoaffective disorder 1:10 dilution 83 954 8.7 137 1272 10.8 0.79
Schizophrenia or Schizoaffective disorder 1:10 dilution NR NR NR NR 4 26 15.4 137 1272 10.8 1.51
Schizophrenia or Schizoaffective disorder 1:320 dilution NR NR NR NR 22 1081 2.0 22 1272 1.7 1.18
Bipolar disorder or Major depressive disorder 1:10 dilution NR NR NR NR 24 148 16.2 137 1272 10.8 1.60
Bipolar disorder or Major depressive disorder 1:320 dilution NR NR NR NR 6 148 4.1 22 1272 1.7 2.40
Steiner et al. (2013)
Schizophrenia 1:10 dilution 3 45 6.7 1 230 0.4 16.36
Schizophrenia 1:10 dilution 7 74 9.5 1 230 0.4 23.93
Schizophrenia 1:320 dilution 0 45 0.0 0 230 0.0 Not estimable
Schizophrenia 1:320 dilution 4 74 5.4 0 230 0.0 29.43
Major depressive disorder 1:10 dilution 2 35 5.7 1 230 0.4 13.88
Major depressive disorder 1:10 dilution 0 35 0.0 1 230 0.4 2.15
Major depressive disorder 1:320 dilution 1 35 2.9 0 230 0.0 20.04
Major depressive disorder 1:320 dilution 0 35 0.0 0 230 0.0 Not estimable
Dickerson et al. (2013)
Mania (admission) a 75th percentile NR 57 .. NR 207 .. 2.79
Mania (4 ± 2.3 d) 75th percentile NR 44 .. NR 207 .. 3.65
Mania (191 ± 12.9 d) 75th percentile NR 38 .. NR 207 .. 2.11
Mania (admission) 90th percentile NR 57 .. NR 207 .. 5.27
Mania (4 ± 2.3 d) 90th percentile NR 44 .. NR 207 .. 5.25
Mania (191 ± 12.9 d) 90th percentile NR 38 .. NR 207 .. Not estimable
Schizophrenia or Schizoaffective disorder b 90th percentile NR 234 .. NR 207 .. Not estimable
Bipolar disorder c 90th percentile NR 28 .. NR 207 .. Not estimable
Haussleiter et al. (2012)
Schizophrenia 1:10 dilution 0 44 0.0 .. 0 .. Not estimable
Schizoaffective disorder 1:10 dilution 0 4 0.0 .. 0 .. Not estimable
Tsutsui et al. (2012)
Schizophrenia, Schizoaffective, or BEP NR NR NR NR NR 4 53 7.5 .. 0 .. Not estimable
Schizoaffective disorder with narcolepsy NR NR NR NR NR 2 3 66.7 .. 0 .. Not estimable
Masdeu et al. (2012)
Schizophrenia 1:200 dilution 0 80 0.0 0 40 0.0 Not estimable
Zandi et al. (2011)
Schizophrenia visual score>1 3 31 9.7 0 23 0.0 5.77
Schizophrenia visual score>1 0 22 0.0 0 23 0.0 Not estimable
Bipolar or Major depressive disorders visual score>1 0 7 0.0 0 23 0.0 Not estimable
Rhoads et al. (2011)
Schizophrenia NR NR NR NR NR 0 7 0.0 0 3 0.0 Not estimable
Govorin et al. (2011)
Schizophrenia NR NR 23 .. NR 10 .. Not estimable
Odds higher in
Healthy controls
Odds higher in
Psychiatric group
Fig. 1. Odds of N-methyl-D-aspartate receptor antibody seropositivity in participants with schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder vers s healthy controls, by disease state severity and dilution cut-off
point seropositivity thresholds. A. Admitted during a manic or hypomanic episode and an admitting diagnosis of Bipolar I disorder (single manic episode, most recent episode manic, r most recent episode mixed); Bipolar II disorder (most recent
episode hypomanic); or Schizoaffective disorder, bipolar type (manic, hypomanic, or mixed state). B. Community sample, recruited during chronic or multi-episode disease states. C. mitted with symptoms of depression with an admission diag-
nosis of bipolar disorder. Note that for a given study, the same participants often contribute to the data onmore than one row. BEP= brief episode psychosis; CI = conﬁdence interva First ep. = First episode; Multi ep. =Multi-episode; NR=not
reported.
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Psychiatric group Healthy controls % Weight
Events   Total    % Events   Total    %
Hammer et al. (2013), 1:320 dilution 28 1229 2.3 22 1272 1.7 41.37 1.32
Steiner et al. (2013), 1:320 dilution 5 189 2.6 0 230 0.0 10.89 13.74
Dickerson et al. (2013), 90th percentile NR 57 .. NR 207 .. 37.40 5.27
Zandi et al. (2011), visual score > 1 3 60 5.0 0 23 0.0 10.34 2.86
Masdeu et al. (2012), 1:200 dilution 0 80 0.0 0 40 0.0 0.00 Not estimable
Total .. 1615 .. .. 1772 .. 100.00 3.10
Heterogeneity: 2 = 9.35, df = 3, I2 = 67.9%, P = .025 
Test of overall effect: z = 2.03, P = .043          0.01     0.1 1    10     100
Odds higher in
Healthy controls
Odds higher in
Psychiatric group
Psychiatric group Healthy controls % Weight
Events    Total % Events    Total   %
Hammer et al. (2013), 1:10 dilution 93 1229 7.6 137 1272 10.8 40.52 0.68
Steiner et al. (2013), 1:10 dilution 12 189 6.3 1 230 0.4 22.40 15.53
Dickerson et al. (2013), 75th percentile NR 57 .. NR 207 .. 37.08 2.79
Rhoads et al. (2011), 1:10 dilution 0 7 0.0 0 3 0.0 0.00
Total .. 1482 .. .. 1712 .. 100.00 2.31
(0.51–0.89)
(2.00–120.53)
(1.33–5.85)
(0.55–9.73)
Heterogeneity: 2 = 20.18, df = 2, I2 = 90.1%, P < .001 
Test of overall effect: z = 1.14, P = .25          0.01     0.1  1        10        100
Odds higher in
Healthy controls
Odds higher in
Psychiatric group
A
B
Odds Ratio (95% CI)
Odds Ratio (95% CI)
Not estimable
High-specificity
Low-specificity
(1.04–9.27)
(0.14–57.57)
(2.39–11.62)
(0.76–250.14)
(0.75–2.33)
Fig. 2. Odds of N-methyl-D-aspartate receptor antibody seropositivity for comparisons between schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder
versus healthy controls, based on (A) high-speciﬁcity and (B) low-speciﬁcity seropositivity thresholds. Summary estimates and heterogeneity were computed using DerSimonian and
Laird's random effects model. Square data markers and horizontal error bars indicate individual study point estimates of the odds ratio and the corresponding 95% conﬁdence intervals,
respectively. The size of each square is directly proportional to theweight the point estimate contributes to the pooled summary estimate (diamond). The solid vertical line reﬂects the null
hypothesis (odds ratio = 1.00); point estimates with error bars that overlap with this line, are statistically insigniﬁcant at α= 0.05. CI = conﬁdence interval; NR = not reported.
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from 1:320 to 1:10 had the effect of decreasing the pretest odds of
NMDAR antibody seropositivity more than four-fold among those
with schizophrenia or schizoaffective disorder as well as among
those with bipolar or major depressive disorders. In contrast, doing
so resulted in a nearly seven-fold decrease in seropositivity among
healthy controls. All three of these intra-group comparisons were
statistically signiﬁcant. A similar but less pronounced trend was
observed for the study by Steiner et al. (2013). A third study also pro-
vided outcome data for more than one seropositivity threshold (90th
and 75th percentiles of healthy control titers; Dickerson et al., 2013).
However, it could not be included in these analyses because of
missing event data for the number and proportion of seropositive
participants underlying the reported odds ratios and 95% CIs (we
were unable to obtain these data from the authors). Although the
odds ratio for NMDAR antibody seropositivity for the comparison be-
tween acute mania and healthy control groups was higher with the
90th percentile cut-off point, the change in seropositivity within
each group accounting for the ratio change is unclear.
The overall distribution of immunoglobulin class NMDAR antibodies
among seropositive participants in the psychiatric group, by disorder,
NMDAR subunit(s), disease states, and included study are summarized
in Fig. 4, Tables S3, and S4.
3.3. Secondary outcome: N-methyl-D-aspartate receptor antibody titers
Two studies provided longitudinal data on NMDAR antibody
serum titers in psychiatric disorders. For the study by Dickersonet al. (2013), we estimated values of serum NMDAR antibody titers
from a graph in the original report because of missing outcome
data on the absolute titer values and associated test statistics (we
were unable to obtain these data from the authors). Serum titers of
IgG class NMDAR antibodies against NR2A/NR2B subunits were sig-
niﬁcantly higher among participants with acute mania, as compared
with healthy controls (P b .01). Among those with acute mania, titers
decreased by about 13% after an average of 4.0 ± 2.3 days (~1.6 vs
~1.4 ng/mL) and by about 25% after an average of 191.0 ± 12.9 days
(~1.6 vs ~1.2 ng/mL): test of trend for antibody titers vs. time
(P b .007). There were no signiﬁcant differences in average serum titers
of IgG class NMDAR antibodies against NR2A/NR2B subunits for compar-
isons between each of the remaining psychiatric groups and the healthy
control group.
Govorin and Vasil'eva (2011) collected serum samples from 23
participants with ﬁrst episode schizophrenia and 10 healthy controls.
Mean ± standard deviation serum NMDAR antibody titers of unspeci-
ﬁed immunoglobulin class against NR2A/NR2B subunits were signiﬁ-
cantly higher among those with acute schizophrenia, as compared
with healthy controls (1.94 ± 0.76 vs 0.75 ± 0.32 ng/mL; mean differ-
ence, 1.19; 95%CI 0.68–1.70; P= .0001). At eight-week follow-up, titers
remained higher among the schizophrenia group (1.23± 0.38 vs 0.75±
0.32 ng/mL; mean difference, 0.48; 95% CI, 0.20–0.76; P b .0001).
Levels were about 58% lower than at baseline (1.94 ± 0.76 vs 1.23 ±
0.38 ng/mL; mean difference, 0.71; 95% CI, 0.35–1.07; P = .002). The
test of trend for the effect of time on antibody titers was statistically sig-
niﬁcant (P b .0002). In addition, among those in the schizophrenia
group the authors found signiﬁcant positive correlations between
Effect of disease state First episode Chronic % Weight Odds Ratio (95% CI)
Events Total % Events Total %
Hammer et al. (2013), SCZ/SCZA, 1:10 dilution 6 101 5.9 83 954 8.7 74.18 0.66
Zandi et al. (2011), SCZ, visual score > 1 3 31 9.7 0 22 0.0 25.82 5.53
Total 9 132 6.8 83 976 8.5 100.00 1.15
Heterogeneity: 2 = 1.76, df =1, I2 = 43.2%, P = .19
Test of overall effect: z = 0.15, P = .88
  0.01       0.1 1      10         100
Odds higher in
Chronic
Odds higher in
First episode
Effect of seropositivity threshold 1:10 dilution 1:320 dilution % Weight Odds Ratio (95% CI)
Events Total % Events Total %
Hammer et al. (2013), All participants 254 2501 10.2 50 2501 2.0 73.65 5.54
Steiner et al. (2013), All participants 13 419 3.1 5 419 1.2 26.35 2.65
Total 267 2920 9.1 55 2920 1.9 100.00 4.56
Heterogeneity: 2 = 1.77, df = 1, I2= 43.6%, P = .18
Test of overall effect: z = 4.67, P < .001
  0.01       0.1 1      10         100
Odds higher at
1:320 dilution
Odds higher at
1:10 dilution
A 
B 
(0.28–1.56)
(0.27–112.60)
(0.19–7.24)
(4.07–7.54)
(0.94–7.50)
(2.41–8.62)
Fig. 3. Odds ofN-methyl-D-aspartate receptor antibody seropositivity for comparisons between (A) ﬁrst-episode versus chronic schizophrenia or schizoaffective disorder, and (B) psychi-
atric plus healthy controls at high-speciﬁcity versus low-speciﬁcity seropositivity thresholds. Summary estimates and heterogeneity were computed using DerSimonian and Laird's ran-
dom effects model. Square datamarkers and horizontal error bars indicate individual study point estimates of the odds ratio and the corresponding 95% conﬁdence intervals, respectively.
The size of each square is directly proportional to the weight the point estimate contributes to the pooled summary estimate (diamond). The solid vertical line reﬂects the null hypothesis
(odds ratio = 1.00); point estimates with error bars that overlap with this line, are statistically insigniﬁcant at α= 0.05. CI = conﬁdence interval; NR = not reported.
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Fig. 4. Distribution of immunoglobulin class antibodies against N-methyl-D-aspartate receptors among seropositive participants with psychiatric disorders, by (A) N-methyl-D-aspartate
receptor subunits and (B) disease states. The distribution of data illustrated here, by included study, is shown in Tables S4 and S5 in the supplement. Ig= immunoglobulin. For each row,
events shownaremutually exclusive (e.g., an individualwith IgA and IgMantibodies againstNR1 is only counted in the IgA+ IgMbar, and not in either the IgA [alone] or IgM [alone] bars).
255D.M. Pearlman, S. Najjar / Schizophrenia Research 157 (2014) 249–258
256 D.M. Pearlman, S. Najjar / Schizophrenia Research 157 (2014) 249–258NR2A/NR2B antibody titers and levels of brain-derived neurotropic
factor (r = 0.42, P b .05), glial acid ﬁbrillary protein (r = 0.46,
P b .05), and particularly with neuron-speciﬁc enolase (r = 0.77,
P b .005).
4. Discussion
To our knowledge, this is the ﬁrst systematic review of studies pro-
viding evidence on the relationships between NMDAR antibody sero-
positivity or titers and schizophrenia, schizoaffective disorder, bipolar
disorder, and major depressive disorder. There are several ﬁndings of
note. First, we found that individuals with these psychiatric disorders
are collectively about three times more likely to have elevated
NMDAR antibody titers compared with healthy controls based on
high-speciﬁcity, but not low-speciﬁcity, seropositivity thresholds. In
contrast to prior reports indicating that psychotropic medication can
induce serum autoantibody production (Schwartz et al., 2009; Shen
et al., 2009), that our results indicate the odds of NMDAR antibody sero-
positivity and/or average titers are both higher among participants with
ﬁrst-episode presentations of psychiatric disorders relative to healthy
controls in several (Govorin and Vasil'eva, 2011; Zandi et al., 2011;
Steiner et al., 2013), though not all included studies (Masdeu et al.,
2012; Hammer et al., 2013), supports the possibility anticipated by
Ezeoke et al. (2013) that the association between NMDAR antibodies
and selectedpsychiatric disorders can be observed independent ofmed-
ication effects. Second, we found that NMDAR antibody seropositive
participants with ﬁrst-episode or acute schizophrenia or schizoaffective
disorder, bipolar or major depressive disorders had various combina-
tions of IgG, IgM, and/or IgA class NMDAR antibodies against NR1,
NR1/NR2B, and/or NR2A/NR2B subunits. With the exception of 3% (4
of 132) of participants with bipolar or major depressive disorders
from one study ( Hammer et al., 2013), none of these participants had
IgG class NMDAR antibodies against the NR1 subunit alone. This sug-
gests that our ﬁndingof increased odds of NMDAR antibody seropositiv-
ity cannot be attributed to the inadvertent inclusion of undiagnosed
anti-NMDAR encephalitis cases in psychiatric groups. Third, both stud-
ies reporting longitudinal data on serum titers of NMDAR antibodies
based on ELISAs documented signiﬁcant reductions in antibody titers
over time (Govorin and Vasil'eva, 2011; Dickerson et al., 2013). These
ﬁndings underscore the possibility that a subset of seronegative partic-
ipants may have previously been seropositive during ﬁrst-episode or
acute disease states, as previously suggested (Lennox et al., 2009;
Zandi et al., 2011; Haussleiter et al., 2012). Fourth, although there is
no optimal dilution cut-off point with established sensitivity and speci-
ﬁcity for distinguishing individuals with psychiatric disorders from
healthy controls based on NMDAR antibody seropositivity, results of
the two studies contributing data to the dilution-stratiﬁed subgroup
analysis suggest that 1:10 is a sub-optimal standard in this regard
(Hammer et al., 2013; Steiner et al., 2013). This underscores the
need for future investigations aimed at determining the optimal di-
lution cut-off point in these populations, parallel to what has been
done in studies of acute cortical ischemia and systemic lupus erythe-
matosus, which used a receiver–operator characteristic curve
(Dambinova et al., 2003) and standardized the cut-off based on a
given number of standard deviations above the average controls' ti-
ters (Arinuma et al., 2008), respectively.
Several factors might contribute to the association between
serum NMDAR antibodies and schizophrenia, schizoaffective disor-
der, bipolar disorder and major depressive disorder. These include
(a) genetic predisposition to autoimmunity, (b) molecular mimicry
secondary to infection, and (c) hyperglutamatergic-dependent,
NMDAR-mediated, neuronal excitotoxicity with secondary intrathe-
cal NMDAR antibody synthesis. Regarding genetic predisposition to
autoimmunity, in 2009, three independent genome-wide associa-
tion studies identiﬁed a common risk variant for schizophrenia and
bipolar disorder on chromosome 6.22p1, a segment containinggenes that encode the major histocompatibility complex (MHC)
class II proteins involved in human leukocyte antigen (HLA) presen-
tation (International Schizophrenia et al., 2009; Shi et al., 2009;
Stefansson et al., 2009). In 2013, a fourth independent genome-
wide association study, which addressed several potential limita-
tions concerning the earlier three studies, replicated these ﬁndings
(Walters et al., 2013). Epidemiological data demonstrate robust per-
sonal and familial associations between psychotic as well as mood
disorders and autoimmune diseases (Gilvarry et al., 1996; Eaton
et al., 2006; Eaton et al., 2010; Benros et al., 2011; Chen et al.,
2012; Benros et al., 2013; Benros et al., 2014a; Benros et al.,
2014b). Hammer et al. (2013) speciﬁcally assessed the relationship
between MHC class II mutations and NMDAR antibody seropositivi-
ty, ﬁnding a nominally signiﬁcant association with a single nucleo-
tide polymorphism in the HLA-A03 gene (P = 0.01). However, the
authors found a mutation reaching genome-wide signiﬁcance in
rs524991 (OR, 2.22; 95% CI, 1.65–3.00; P b 6.1 ×10−8). This gene re-
sides 218.59 kb away from the transcription factor nuclear factor I sub-
type A, which is putatively implicated in neuroprotection and neuronal
plasticity following NMDAR activation (Zheng et al., 2010), but not in au-
toimmunity per se.
Regarding molecular mimicry secondary to infection, epidemiologi-
cal studies provide consistent evidence of an association between psy-
chotic as well as mood disorders and prior history of infection (Yolken
and Torrey, 1995; Torrey et al., 1997). Along these lines, studies have
also implicated several speciﬁc pathogens, including herpes simplex
virus type II (Brown et al., 2005; Mortensen et al., 2007), inﬂuenza
(Brown and Derkits, 2010) and toxoplasma gondii (Buka et al., 2001;
Torrey et al., 2007; Buka et al., 2008; Dickerson et al., 2014). Herpes sim-
plex virus has also recently been linked to anti-NMDAR encephalitis,
though the direction of this association is unclear (Prüss et al., 2012;
Armangue et al., 2014). Hammer et al. (2013) reported a signiﬁcant as-
sociation between NMDAR antibody seropositivity and prior exposure
to inﬂuenza among participants with schizophrenia or schizoaffective
disorder.
Hyperglutamatergic-dependent NMDAR-mediated excitotoxicity
with secondary intrathecal NMDAR antibody synthesismay represent an-
other contributing factor to NMDAR antibody mediated neuropsychiatric
sequelae. In acute cortical ischemia, NMDAR-mediated excitotoxicity is
thought to induce serine-protease cleavage and release of NMDAR
subunit peptide fragments into the blood, where they are recognized as
foreign antigens, prompting autoantibody synthesis and opsonization
(Dambinova et al., 2003; Bokesch et al., 2006; Dambinova et al., 2012).
Although mood disorders are also known to be associated with
hyperglutamatergia (Najjar et al., 2013a), the relevance of this mecha-
nism to NMDAR antibody seropositivity in mood disorders is unknown.
The functional signiﬁcance of serum NMDAR antibodies found in
psychiatric disorders, from directly pathogenic to biomarkers of
concomitant autoimmunity to mere epiphenomena, remains to be clar-
iﬁed. Emerging evidence links blood–brain barrier dysfunction and
hyperpermeability to primary psychotic and mood disorders (Shalev
et al., 2009; Bechter et al., 2010; Najjar et al., 2013a; Najjar et al.,
2013b). An independent line of evidence suggests that increased
blood–brain barrier permeability is necessary for NMDAR antibody-
induced neuropsychiatric symptomatology (Arinuma et al., 2008;
Lauvsnes and Omdal, 2012; Hammer et al., 2013; Yoshio et al., 2013).
IgG NMDAR antibodies against NR2A/NR2B subunits in cerebrospinal
ﬂuid are substantially more predictive of neuropsychiatric systemic
lupus erythematosus than are those in serum (Lauvsnes and Omdal,
2012). A recent study showed that IgG class antibodies against NR2A/
NR2B subunits obtained from cerebrospinal ﬂuid of individuals with
neuropsychiatric systemic lupus erythematosus can promote inﬂam-
matory and vascular abnormalities that increase blood–brain barrier
permeability by cross-reacting with endothelial double-stranded DNA
in a dose-dependent manner (Yoshio et al., 2013). These inﬂammatory
and vascular abnormalities included increased endothelial expression of
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ecule 1 and intercellular adhesionmolecule 1, and increased endothelial
production of interleukin-6 (IL-6) and IL-8 (but not tumor necrosis fac-
tor α or IL-1β), in association with NF-κB activation. Although many of
these same abnormalities have been described in primary psychotic and
mood disorders (Najjar et al., 2013a), the effects of NMDAR antibodies
on blood–brain barrier integrity in these disorders remain unknown.
Hammer et al. (2013) found a signiﬁcant positive association between
risk factors for blood–brain barrier damage (history of neurotrauma
and birth complications) and severity of neuropsychiatric features in
NMDAR antibody seropositive participants with schizophrenia or
schizoaffective disorder.
Whereas the majority of evidence for the functional relevance of
NMDAR antibodies has focused on the nowwell-established pathogenic
role of IgG class antibodies in anti-NMDAR encephalitis, the pathogenic-
ity of IgA (Pruss et al., 2012a; Hammer et al., 2013) and IgM (Choe et al.,
2013) class NMDAR antibodies has also been demonstrated in vitro and
in vivo. Prüss and colleagues showed that in a cohort of seven patients
with cognitive impairment and reduced metabolic brain activity, ele-
vated serum IgA class (cerebrospinal ﬂuid in three of seven), but
not IgG class, NMDAR antibodies substantially decreased the expres-
sion of NMDARs and synaptophysin, and inhibited NMDAR-
mediated currents in a dose-dependent manner in vitro (via NR1-
HEK cell-based assay; Pruss et al., 2012b). Further, these immuno-
logic and clinical abnormalities were reversed after removing pa-
tients' serum from the culture media and initiating immunotherapy
plus plasma exchange (Pruss et al., 2012b). Several authors have
also hypothesized that NMDAR antibodies might exert differential
functional effects according to the underlying neurobiology of psy-
chiatric disorders (Lapteva et al., 2006; Gono et al., 2011). That is,
given that NMDAR hypofunction is implicated in schizophrenia and
that NMDAR hyperfunction is implicated in major depressive disor-
der (Najjar et al., 2013a), it is conceivable that NMDAR antibodies
might exacerbate the neuropsychiatric symptoms of schizophrenia
by augmenting NMDAR hypofunction, while ameliorating those of
mood disorders. This is analogous to either pro-psychotic or antide-
pressant effects of NMDAR antagonists, such as ketamine, MK-801,
or phencyclidine.
Our study has several important limitations. First, included studies
largely provided data on clinical and demographic characteristics at
the group rather than the individual level of analysis. As such, we
were unable to perform regression analyses aimed at assessing the
potential for confounding associated with these characteristics. Second,
only four of the included studies explicitly reported blind outcome
assessment of case/control status. Third, heterogeneous methods in
the included studies might have inﬂuenced the pretest odds of
NMDAR antibody seropositivity. Fourth, variability in the combinations
of immunoglobulin classes and NMDAR subunits assessed across stud-
ies increases the risk of detection bias. One study did not detect any
NMDAR antibody seropositivity among participants with ﬁrst-episode
schizophrenia, speciﬁcally assayed for IgG class NMDAR antibodies
against the NR1 subunit, but not for other immunoglobulin classes or
NMDAR subunits (Masdeu et al., 2012). Fifth, none of the studies
assayed antibody seropositivity against NR2A or NR2B subunits alone.
ELISA methods that can distinguish between these subunits were re-
cently described (Gono et al., 2011). Whereas the more commonly
assayed peptide DWEYSVWLSN does not disambiguate between these
subunits, the N-terminal domain sequences DWDYS and DEWDY are
speciﬁc to NR2A andNR2B, respectively (Gono et al., 2011). Future stud-
ies should do so, not only to minimize the risk of detection bias, but also
because NR2A and NR2B subunits have distinctive physiologic (von
Engelhardt et al., 2009; Paoletti et al., 2013) and pathologic (Li et al.,
2010; Gono et al., 2011) roles. Sixth, the estimates of NMDAR antibody
seropositivity we report are based on a combination of different immu-
noassay techniques that are characterized by differences in their inher-
ent reliability (e.g., results from cell-based assays are generallyconsidered more valid than those from ELISAs). Last, the possibility
that other methodological factors not reported might have signiﬁcantly
inﬂuenced the sensitivity and speciﬁcity of immunostaining assays used
across studies cannot be excluded.
In conclusion, we found that individuals with schizophrenia or
schizoaffective, bipolar, or major depressive disorders are collectively
about three times more likely to have elevated NMDAR antibody titers
compared with healthy controls based on high-speciﬁcity, but not
low-speciﬁcity, seropositivity thresholds, though considerable method-
ological and statistical heterogeneity exists. Evidence concerning the
effect of disease state and timeof serumacquisition is varied and consis-
tent, repectively. Adequately powered longitudinal studies employing
standardized assay methods and seropositivity threshold deﬁnitions,
and quantifying NMDAR antibodies in both sera and cerebrospinal
ﬂuid are needed to further elucidate the clinical and pathophysiological
implications of this association.
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